We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
51
Minerva Neurosciences
NERV
$183M
$6.57M 0.37%
101,317
– –
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.55M 0.37%
1,322,994
– –
CDTX
53
DELISTED
Cidara Therapeutics
CDTX
$6.45M 0.37%
41,318
+2,650
+7% +$465K
VIVE
54
DELISTED
VIVEVE MED INC
VIVE
$5.94M 0.34%
+939
New +$4.57M
HUM icon
55
Humana
HUM
$47.6B
$5.67M 0.32%
27,500
+25,273
+1,135% +$5.23M
SRRA
56
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.67M 0.32%
+92,593
New +$5.38M
CLSD
57
DELISTED
Clearside Biomedical
CLSD
$5.65M 0.32%
47,471
– –
NVTA
58
DELISTED
Invitae Corporation
NVTA
$5.31M 0.3%
480,000
-20,000
-4% -$192K
PFNX
59
DELISTED
Pfenex Inc.
PFNX
$5.19M 0.3%
892,847
-21,529
-2% -$162K
ZYNE
60
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.05M 0.29%
251,328
-590,800
-70% -$11.7M
SIOX
61
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.63M 0.26%
+38,750
New +$4.06M
NEPT
62
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$4.61M 0.26%
4,657
– –
SGYP
63
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$4.56M 0.26%
978,100
+487,800
+99% +$2.83M
JAZZ icon
64
Jazz Pharmaceuticals
JAZZ
$15.6B
$4.35M 0.25%
30,000
-22,000
-42% -$2.87M
PPHMP
65
DELISTED
Peregrine Pharmaceuticals Inc. 10.50% Series E Convertible
PPHMP
$4.34M 0.25%
200,000
– –
DERM
66
DELISTED
Dermira, Inc.
DERM
$3.94M 0.22%
115,583
-210,000
-64% -$6.78M
EYPT icon
67
EyePoint Inc
EYPT
$316M
$3.92M 0.22%
227,971
– –
ABEOW
68
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$3.69M 0.21%
1,259,636
– –
ADMA icon
69
ADMA Biologics
ADMA
$1.93B
$3.52M 0.2%
721,102
– –
AMGN icon
70
Amgen
AMGN
$203B
$3.28M 0.19%
+20,000
New +$3.32M
OTLK icon
71
Outlook Therapeutics
OTLK
$164M
$3.17M 0.18%
7,387
-419
-5% -$208K
ABEO icon
72
Abeona Therapeutics
ABEO
$313M
$3.11M 0.18%
24,915
-8,772
-26% -$1.13M
OCGN icon
73
Ocugen
OCGN
$337M
$3.08M 0.18%
29,630
– –
AVEO
74
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$3.01M 0.17%
510,881
+200,000
+64% +$1.44M
XENE icon
75
Xenon Pharmaceuticals
XENE
$5.45B
$2.9M 0.16%
723,853
-16,419
-2% -$129K
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.